Hearts & Minds Blog

The Promise of ETC-1002 for Patients at Risk of Cardiovascular Disease

Noah Rosenberg

Chief Medical Officer

Many years ago, as an attending physician in an academic emergency department, I was surprised to see a number of patients presenting with advanced cardiovascular disease (CVD). What made this so unusual was that these patients had no known “traditional” CVD risk factors, such as smoking or high blood pressure, but were all relatively young–in their 30s or 40s–and obese. Their CVD had progressed beyond our ability to reverse years of damage. Oftentimes, I felt helpless and wanted to do something to help prevent people… more

Going with Your Gut

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Sometimes in science, you have to go with your gut. Years ago, my gut instinct told me that a drug I was working on would be successful, even though it was still early in development and several effective competitors were already on the market. I believed in this drug so much that I begged the company multiple times not to discontinue the program, and pleaded with them for the necessary funds to continue development. I wrote memos to the business people at Warner-Lambert saying that… more

Getting the Band Back Together

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last year, one of the country’s most brilliant scientists called me and asked if I wanted to help him change the lives of millions of people – again. Two decades ago, that scientist, Roger Newton, helped create the statin Lipitor, which turned out to be the best selling pharmaceutical drug of all time. Because of his contribution to developing that medicine, millions of people have lived longer and healthier lives. I met Roger initially in 1998, just after he started the first Esperion Therapeutics…. more